London-based Samphire Neuroscience raises €2.1 million to launch wearable that targets PMS and menstrual pain

London-based Samphire Neuroscience raises €2.1 million to launch wearable that targets PMS and menstrual pain Medtech startup Samphire Neuroscience secured €2.1 million in pre-seed funding to launch Nettle, their medical-grade neurostimulation wearable. Read the article on EU Startups > Read More from the Global Wellness News ™

The Trend in the News: A Wellness Check for Weight Loss Drugs in 2024

Trend: A Wellness Check for Weight Loss Drugs in 2024 Week of Feb 21st, 2024 The Race Is on to Stop Ozempic Muscle Loss–The New York Times, February 8, 2024  A great overview of how fitness brands, nutrition startups, and drugmakers all want to solve a common issue with weight loss drugs: significant muscle loss that can happen. Luxury gyms are offering strength-training programs specifically marketed…

Trend: A Wellness Check for Weight Loss Drugs in 2024

Trend: A Wellness Check for Weight Loss Drugs in 2024 The arrival of the “Ozempics” shook up the weight-loss-focused wellness world, which is now beginning to figure out its future role. While some businesses started prescribing the new drugs, more companies are now creating companion fitness and nutrition programs to combat issues caused by their use. But the long future is integrative drug + wellness…

Croatian longevity startup GlycanAge secures €3.9 million to advance personalized preventative care

Croatian longevity startup GlycanAge secures €3.9 million to advance personalized preventative care GlycanAge, a biotech startup pioneering the field of glycan biomarkers, announced the successful completion of its €3.9 million seed funding round, led by LAUNCHub Ventures and UK-based deep-tech fund Kadmos Capital. Read the article on EU Startups > Read More from the Global Wellness News ™

Save Your Cart
Share Your Cart